Trials / Completed
CompletedNCT05844592
First in Human, Single Ascending Dose Study
A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of INV-101 Administered Orally to Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Innovo Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to evaluate the safety and tolerability of single ascending oral doses of INV-101 in healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INV-101 | subjects will be randomized 3:1 ratio |
Timeline
- Start date
- 2022-04-21
- Primary completion
- 2022-07-16
- Completion
- 2022-08-31
- First posted
- 2023-05-06
- Last updated
- 2023-05-06
Locations
1 site across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05844592. Inclusion in this directory is not an endorsement.